In Situ Liquid‐Liquid Phase Separation of Peptides Into Droplets Targeting Membraneless Organelles for Enhanced Cancer Chemotherapy

W Weishu Wang H Hao Wang (Division of Quantitative Sciences, Department of Oncology Johns Hopkins University School of Medicine Baltimore Maryland USA) Z Zeyu Zhang X Xin Liu B Binbin Hu (State Key Laboratory of Natural and Biomimetic Drugs, Chemical Biology Center, and Department of Chemical Biology at School of Pharmaceutical Sciences) F Feng Tian Z Zhou Ye L Linqi Shi (Key Laboratory of Functional Polymer Materials, Ministry of Education, State Key Laboratory of Medicinal Chemical Biology, Institute of Polymer Chemistry, College of Chemistry, Nankai University, 94 Weijin Road, Tianjin 300071, China) Z Zhilin Yu (Key Laboratory of Functional Polymer Materials, Ministry of Education, State Key Laboratory of Medicinal Chemical Biology, Institute of Polymer Chemistry, College of Chemistry, Nankai University, 94 Weijin Road, Tianjin 300071, China)

Abstract

Abstract Liquid‐liquid phase separation (LLPS) of proteins and nucleic acids into membraneless organelles (MLOs) plays a critical role in sustaining fundamental physiological processes. However, creating artificial coacervate droplets in living cells from exogenous molecules and modulating the functions of MLOs remain challenging. To address this concern, here we reported enzyme‐induced in situ phase separation of peptides into droplets targeting MLO stress granule (SG) for enhanced cancer chemotherapy. The peptide Y SO4 F containing two sulfated tyrosine residues undergoes sulfatase‐responsive LLPS into droplets. Cellular studies confirm in situ phase separation of Y SO4 F selectively in sulfatase‐overexpressing cancer cells. By integrating with appropriate ligands, the in situ‐formed droplets d‐YF‐L SG coacervate with SGs driven by association between the ligand with SG key component protein G3BP2. Mechanistic studies illustrate that the in situ‐formed droplets enhance the cytotoxicity of sorafenib via activating caspase‐dependent apoptosis. Furthermore, animal experiments confirm that administration of the in situ‐formed droplets with sorafenib significantly inhibits tumor growth in murine models bearing tumors, accompanied by an excellent biosafety profile. The findings in this study elucidate an innovative approach for in situ formulation of coacervate droplets within tumor cells and a new material for targeting membraneless organelles, thus providing a promising new strategy for disease organelle‐targeted therapy in the future.

Article Details

Volume / Issue Vol. 37, Issue 28
Published July 01, 2025
ISSN 0935-9648
Publisher Unknown Publisher

Journal Info

Advanced Materials

Unknown Publisher

ISSN: 0935-9648 Physical Sciences

Authors (9)

W

Weishu Wang

H

Hao Wang

Division of Quantitative Sciences, Department of Oncology Johns Hopkins University School of Medicine Baltimore Maryland USA

Z

Zeyu Zhang

X

Xin Liu

B

Binbin Hu

State Key Laboratory of Natural and Biomimetic Drugs, Chemical Biology Center, and Department of Chemical Biology at School of Pharmaceutical Sciences

F

Feng Tian

Z

Zhou Ye

L

Linqi Shi

Key Laboratory of Functional Polymer Materials, Ministry of Education, State Key Laboratory of Medicinal Chemical Biology, Institute of Polymer Chemistry, College of Chemistry, Nankai University, 94 Weijin Road, Tianjin 300071, China

Z

Zhilin Yu

Key Laboratory of Functional Polymer Materials, Ministry of Education, State Key Laboratory of Medicinal Chemical Biology, Institute of Polymer Chemistry, College of Chemistry, Nankai University, 94 Weijin Road, Tianjin 300071, China